N-(N-Boc-piperidin-4-yl)methoxyphthalimide | 143540-03-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: N-(N-Boc-piperidin-4-yl)methoxyphthalimide
• 英文别名: t-butyl 4-((1,3-dioxoisoindolin-2-yloxy)methyl)piperidine-1-carboxylate；tert-butyl 4-[(1,3-dioxoisoindol-2-yl)oxymethyl]piperidine-1-carboxylate
• CAS: 143540-03-8
• 化学式: C₁₉H₂₄N₂O₅
• 分子量: 360.41
• InChiKey: YHTMVAJLXCUCCI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  76.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-(N-Boc-piperidin-4-yl)methoxyphthalimide 在 一水合肼 作用下， 以 甲醇 为溶剂， 反应 1.0h， 以78%的产率得到4-((氨氧基)甲基)哌啶-1-羧酸叔丁酯
  参考文献：
  名称：

  Piperidine-based glycodendrons as protein N-glycan prosthetics

  摘要：

  The generation of homogeneously glycosylated proteins is essential for defining glycoform-specific activity and improving protein-based therapeutics. We present a novel glycodendron prosthetic which can be site-selectively appended to recombinant proteins to create 'N-glycosylated' glycoprotein mimics. Using computational modeling, we designed the dendrimer scaffold and protein attachment point to resemble the native N-glycan architecture. Three piperidine-melamine glycodendrimers were synthesized via a chemoenzymatic route and attached to human growth hormone and the F-c region of human IgG. These products represent a new class of engineered biosimilars bearing novel glycodendrimer structures. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2016.05.050
• 作为产物：
  描述：

  N-羟基邻苯二甲酰亚胺 、 N-Boc-4-哌啶甲醇 在 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 为溶剂， 反应 4.0h， 以94%的产率得到N-(N-Boc-piperidin-4-yl)methoxyphthalimide
  参考文献：
  名称：

  Piperidine-based glycodendrons as protein N-glycan prosthetics

  摘要：

  The generation of homogeneously glycosylated proteins is essential for defining glycoform-specific activity and improving protein-based therapeutics. We present a novel glycodendron prosthetic which can be site-selectively appended to recombinant proteins to create 'N-glycosylated' glycoprotein mimics. Using computational modeling, we designed the dendrimer scaffold and protein attachment point to resemble the native N-glycan architecture. Three piperidine-melamine glycodendrimers were synthesized via a chemoenzymatic route and attached to human growth hormone and the F-c region of human IgG. These products represent a new class of engineered biosimilars bearing novel glycodendrimer structures. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2016.05.050

文献信息

• [EN] HETEROCYCLIC OXIME COMPOUNDS<br/>[FR] COMPOSÉS D'OXIMES HÉTÉROCYCLIQUES
  申请人：NOVARTIS AG

  公开号：WO2011020861A1

  公开（公告）日：2011-02-24

  The invention relates to compounds of formula (I) and salts thereof wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).

  该发明涉及公式(I)的化合物及其盐，其中取代基如规范中所定义；公式(I)的化合物用于治疗人体或动物体，特别是针对c-Met酪氨酸激酶介导的疾病或症状；公式(I)的化合物用于制造治疗此类疾病的药物；包含公式(I)的化合物的药物组合物，可选地与组合伙伴一起，并且用于制备公式(I)的化合物的方法。
• HETEROCYCLIC OXIME COMPOUNDS
  申请人：DAI Miao

  公开号：US20110065708A1

  公开（公告）日：2011-03-17

  The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).

  本发明涉及公式（I）的化合物及其盐： 其中取代基如规范中所定义；公式（I）的化合物用于人或动物体内的治疗，特别是针对c-Met酪氨酸激酶介导的疾病或情况；使用公式（I）的化合物制造治疗此类疾病的药物；包括公式（I）的化合物的制药组合物，可选地与联合伙伴一起使用，以及制备公式（I）的化合物的过程。
• Heterocyclic oxime compounds
  申请人：Dai Miao

  公开号：US08410264B2

  公开（公告）日：2013-04-02

  The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).

  本发明涉及公式(I)的化合物及其盐：其中，取代基如规范中所定义；公式(I)的化合物用于治疗人体或动物体，特别是涉及c-Met酪氨酸激酶介导的疾病或病况；使用公式(I)的化合物制造治疗此类疾病的药物；包括公式(I)化合物的制药组合物，可选地与联合伙伴一起，以及制备公式(I)化合物的过程。
• Heterozyklische Hydroxylamine
  申请人：CIBA-GEIGY AG

  公开号：EP0495750A2

  公开（公告）日：1992-07-22

  Verbindungen der Formel worin X für Methylen, Imino, Sauerstoff oder Schwefel steht und R einen Rest bezeichnet, worin n 0, 1 oder 2 bedeutet, mit der Massgabe, dass n nicht 0 bedeutet, wenn R in Position 2 gebunden ist, und Salze davon haben eine starke spezifische Hemmwirkung auf das Enzym Ornithindecarboxylase. Die Verbindungen der Formel I werden nach an sich bekannten Verfahren hergestellt.

  式中 X 为亚甲基、亚氨基、氧或硫，R 为自由基，其中 n 为 0、1 或 2，但当 R 结合在位置 2 时，n 不为 0 的化合物及其盐类对鸟氨酸脱羧酶有很强的特异性抑制作用。 式 I 的化合物是通过本身已知的方法制备的。
• PENICILLIN-BINDING PROTEIN INHIBITORS
  申请人：VenatoRx Pharmaceuticals, Inc.

  公开号：US20200102331A1

  公开（公告）日：2020-04-02

  Described herein are certain boron-containing compounds, compositions, preparations and their use as modulators of the transpeptidase function of bacterial penicillin-binding proteins and as antibacterial agents. In some embodiments, the compounds described herein inhibit penicillin-binding proteins. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.